[Christine MH-UK]

What I found interesting was that they mentioned that herceptin saves by reducing the costs of metastatic care, since I was sure I had read this before but couldn't remember where, so now at least I have a source for this.

Cost-effectiveness analysis of trastuzumab therapy in patients with early HER-2 positive breast cancer in Brazil.

http://www.abstracts2view.com/sabcs/...S07L_358&terms=

This was based on the HERA trial